Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28957152 | 0.98 | SMPD1 (0.73) | SMPD1PDE4BCNR2THRATHRB | |
| SCHEMBL6588516 | 0.95 | SMPD1 (0.64) | SMPD1PDE4BCNR2KMT2AMAOB | |
| SCHEMBL22502336 | 0.94 | THRA (0.64) | SMPD1PDE4BTHRATHRBKMT2A | |
| SCHEMBL30292269 | 0.91 | SMPD1 (0.62) | SMPD1CNR2THRATHRBKMT2A | |
| SCHEMBL10497717 | 0.91 | SMPD1 (0.62) | SMPD1CNR2THRATHRBKMT2A | |
| SCHEMBL7175524 | 0.91 | PDE4B (0.59) | SMPD1PDE4BKMT2AMAOB | |
| SCHEMBL10498350 | 0.91 | SMPD1 (0.62) | SMPD1CNR2THRATHRBKMT2A | |
| SCHEMBL10498076 | 0.91 | SMPD1 (0.62) | SMPD1CNR2THRATHRBKMT2A | |
| SCHEMBL10498409 | 0.91 | SMPD1 (0.62) | SMPD1CNR2THRATHRBKMT2A | |
| SCHEMBL10497807 | 0.91 | SMPD1 (0.62) | SMPD1CNR2THRATHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | SMPD1 1889/4885PDE4B 1700/4885CNR2 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.